A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Lymphoma, Follicular
Interventions
DRUG

Bevacizumab

DRUG

Rituximab

Trial Locations (22)

19611

Berks Hematology Oncology Associates, West Reading

20817

Center for Cancer and Blood Disorders, Bethesda

National Capital Clinical Research Consortium, Bethesda

29303

Spartanburg Regional Medical Center, Spartanburg

30060

Wellstar Cancer Research, Marietta

30501

Northeast Georgia Medical Center, Gainesville

30901

Medical Oncology Associates of Augusta, Augusta

32256

Integrated Community Oncology Network, Jacksonville

32804

Florida Hospital Cancer Institute, Orlando

33805

Watson Clinic for Cancer Research, Lakeland

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

40207

Baptist Hospital East, Louisville

Norton Cancer Institute, Louisville

42101

Graves-Gilbert Clinic, Bowling Green

45242

Oncology Hematology Care, Cincinnati

47802

Providence Medical Group, Terre Haute

68114

Methodist Cancer Center, Omaha

70809

Hematology Oncology Clinic, LLP, Baton Rouge

72401

Northeast Arkansas Clinic, Jonesboro

07960

Hematology Oncology Associates of Northern NJ, Morristown

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00193492 - A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter